Difference between revisions of "Cervarix"
(→Resources) |
(→Background) |
||
| Line 11: | Line 11: | ||
Cervarix will not protect against all types of Human Papillomavirus.HPV types 16 and 18 are responsible for approximately 70% ofcervical cancer cases. | Cervarix will not protect against all types of Human Papillomavirus.HPV types 16 and 18 are responsible for approximately 70% ofcervical cancer cases. | ||
When a female is vaccinated with Cervarix, the immune system(the body’s natural defence system) will make antibodies against HPV types 16 and 18. | When a female is vaccinated with Cervarix, the immune system(the body’s natural defence system) will make antibodies against HPV types 16 and 18. | ||
| + | |||
'''The Cervarix clinical trial programme''' | '''The Cervarix clinical trial programme''' | ||
| Line 17: | Line 18: | ||
15–25 years. A further Phase III, community-based, randomised clinicaltrial is currently underway in Costa Rica, which | 15–25 years. A further Phase III, community-based, randomised clinicaltrial is currently underway in Costa Rica, which | ||
is sponsored by the National Cancer Institute. | is sponsored by the National Cancer Institute. | ||
| − | |||
==Biographical Information== | ==Biographical Information== | ||
Revision as of 11:29, 5 April 2009
Contents
Background
Introduction
Cervarix is a vaccine intended to protect females against the diseases caused by infection with Human Papillomavirus (HPV) types 16 and 18. These diseases include: - cervical cancer(cancer of the cervix i.e. lower part of the uterus or womb), - precancerous cervical lesions(changes in cells of the cervix that have a risk of turning into cancer).
Cervarix will not protect against all types of Human Papillomavirus.HPV types 16 and 18 are responsible for approximately 70% ofcervical cancer cases. When a female is vaccinated with Cervarix, the immune system(the body’s natural defence system) will make antibodies against HPV types 16 and 18.
The Cervarix clinical trial programme
The pre-licensing programme for Cervarix comprised two major clinical trials (a ‘proof-ofconcept’ Phase IIb study and a larger Phase III trial) encompassing some 19,788 women aged 15–25 years. A further Phase III, community-based, randomised clinicaltrial is currently underway in Costa Rica, which is sponsored by the National Cancer Institute.
Biographical Information
History
Current activities
Views
Affiliations
People
Funding
Clients
Publications, Contact, Resources and Notes
Publications
Contact
- Address:
- Phone:
- Email:
- Website:
Resources
/*http://emc.medicines.org.uk/document.aspx?documentId=20207*/
